Exome Asset Management LLC
Exome Asset Management LLC reported 52 holdings worth US$162M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Exome Asset Management LLC reported 52 holdings worth US$162M as of Jun 30, 2026. Largest: Guardant Health, Inc., Praxis Precision Medicines, Inc. and Tg Therapeutics, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 52
- Value as reported
- US$162M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Guardant Health, Inc. | 67,500 | US$10.1M | 6.2% |
| Praxis Precision Medicines, Inc. | 27,205 | US$9.11M | 5.6% |
| Tg Therapeutics, Inc. | 165K | US$9.06M | 5.6% |
| Cogent Biosciences, Inc. | 211K | US$8.15M | 5.0% |
| Ionis Pharmaceuticals, Inc. | 88,177 | US$6.99M | 4.3% |
| Eli Lilly And Company | 5,492 | US$6.59M | 4.1% |
| Abivax Sa | 46,878 | US$6.25M | 3.9% |
| Alumis Inc. | 204K | US$5.75M | 3.5% |
| Cytokinetics, Incorporated | 60,056 | US$5.12M | 3.2% |
| Enliven Therapeutics, Inc. | 100K | US$5.09M | 3.1% |
| Vera Therapeutics, Inc. | 97,276 | US$4.17M | 2.6% |
| Unitedhealth Group Incorporated | 9,612 | US$4M | 2.5% |
| 10x Genomics, Inc. | 103K | US$3.93M | 2.4% |
| Natera, Inc. | 13,800 | US$3.75M | 2.3% |
| Rhythm Pharmaceuticals, Inc. | 32,209 | US$3.58M | 2.2% |
| Maze Therapeutics, Inc. | 115K | US$3.42M | 2.1% |
| Monte Rosa Therapeutics, Inc. | 137K | US$3.32M | 2.0% |
| Liquidia Corporation | 39,224 | US$3.13M | 1.9% |
| United Therapeutics Corporation | 5,410 | US$2.93M | 1.8% |
| Glaukos Corporation | 19,862 | US$2.78M | 1.7% |
| Arrowhead Pharmaceuticals, Inc. | 32,214 | US$2.63M | 1.6% |
| Agios Pharmaceuticals, Inc. | 70,500 | US$2.62M | 1.6% |
| Crescent Biopharma, Inc. | 128K | US$2.3M | 1.4% |
| Boston Scientific Corporation | 48,347 | US$2.06M | 1.3% |
| Penumbra, Inc. | 6,300 | US$1.99M | 1.2% |
| Intuitive Surgical, Inc. | 4,908 | US$1.95M | 1.2% |
| Viking Therapeutics, Inc. | 47,861 | US$1.87M | 1.2% |
| Ocular Therapeutix, Inc. | 182K | US$1.78M | 1.1% |
| Equillium, Inc. | 553K | US$1.77M | 1.1% |
| Corbus Pharmaceuticals Holdings, Inc. | 185K | US$1.73M | 1.1% |
| Cytomx Therapeutics, Inc. | 460K | US$1.73M | 1.1% |
| Verastem, Inc. | 429K | US$1.64M | 1.0% |
| Nektar Therapeutics | 22,417 | US$1.56M | 0.97% |
| Clearpoint Neuro Inc. | 83,636 | US$1.49M | 0.92% |
| Insmed Incorporated | 13,873 | US$1.48M | 0.91% |
| Caris Life Sciences, Inc. | 78,180 | US$1.39M | 0.86% |
| Bridgebio Pharma, Inc. | 18,359 | US$1.37M | 0.84% |
| Zenas Biopharma, Inc. | 52,443 | US$1.33M | 0.82% |
| Establishment Labs Holdings Inc. | 13,100 | US$1.12M | 0.69% |
| Relay Therapeutics, Inc. | 47,531 | US$889K | 0.55% |
| Geron Corporation | 624K | US$799K | 0.49% |
| Bright Minds Biosciences Inc. | 10,110 | US$710K | 0.44% |
| Compass Therapeutics, Inc. | 276K | US$605K | 0.37% |
| Replimune Group, Inc. | 40,361 | US$447K | 0.28% |
| Arbutus Biopharma Corporation | 50,166 | US$241K | 0.15% |
| Avalo Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Elevance Health, Inc. | 0 | US$0 | 0.00% |
| Lipocine Inc. | 0 | US$0 | 0.00% |
| Nextcure, Inc. | 0 | US$0 | 0.00% |
| Palisade Bio, Inc. | 0 | US$0 | 0.00% |
| Soleno Therapeutics, Inc. | 0 | US$0 | 0.00% |
| 4d Molecular Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Apellis Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related